121 related articles for article (PubMed ID: 6106335)
41. [Urinary excretion of catecholamines and 3-methoxy-4 hydroxy-mandelic acid in chronic schizophrenic patients undergoing Triperidol treatment].
Masiak M; Zawiślak H
Psychiatr Pol; 1973; 7(6):637-43. PubMed ID: 4773051
[No Abstract] [Full Text] [Related]
42. Role of the cholinergic system in the pathology and treatment of schizophrenia.
Scarr E; Dean B
Expert Rev Neurother; 2009 Jan; 9(1):73-86. PubMed ID: 19102670
[TBL] [Abstract][Full Text] [Related]
43. [Excretion of vanillic acid and homovanillic acid and tissue distribution of catecholamines and their metabolites in mice with various levels of pigmentation].
Orgacka H; Zbytniewski Z
Endokrynol Pol; 1991; 42(3):471-9. PubMed ID: 1364497
[TBL] [Abstract][Full Text] [Related]
44. [Dynamics of the remission of acute schizophrenic episodes during psychopharmacologic treatment].
Sverdlov LS
Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(5):737-43. PubMed ID: 6115527
[TBL] [Abstract][Full Text] [Related]
45. [Evaluation of the usefulness for measuring catecholamines and their principle metabolites in the diagnosis of pheochromocytoma].
Wocial B; Januszewicz W; Gryglas P; Januszewicz A; Feltynowski T; Lapiński M
Przegl Lek; 1997; 54(11):793-8. PubMed ID: 9501691
[TBL] [Abstract][Full Text] [Related]
46. [Predicting the effect of psychopharmacotherapy in schizophrenic patients].
Dikiĭ NT
Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):110-5. PubMed ID: 6121436
[TBL] [Abstract][Full Text] [Related]
47. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
48. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
49. Changes in the excretion of catecholamines and their metabolites in patients with essential hypertension during sodium intake restriction.
Wocial B; Januszewicz W; Chodakowska J; Feltynowski T
Cor Vasa; 1981; 23(3):222-8. PubMed ID: 6790225
[TBL] [Abstract][Full Text] [Related]
50. [Catecholamine and indoleamine metabolism in groups of patients with paranoid and simple forms of schizophrenia].
Gamaleia NB
Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(5):700-8. PubMed ID: 6168149
[TBL] [Abstract][Full Text] [Related]
51. Implications of catecholamine systems of the brain in schizophrenia.
Matthysse S
Res Publ Assoc Res Nerv Ment Dis; 1974; 53():305-15. PubMed ID: 4155111
[No Abstract] [Full Text] [Related]
52. [Dynamics of neurovegetative indices in children with bronchial asthma].
Kolesov DV; Tiurin NA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(10):1445-9. PubMed ID: 5709168
[No Abstract] [Full Text] [Related]
53. [Psychopharmacotherapy of slowly progressive hypochondriacal schizophrenia].
Smulevich AB; Basov AM; Dubnitskaia EB; Izmaĭlova LG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(11):1583-7. PubMed ID: 42244
[TBL] [Abstract][Full Text] [Related]
54. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661
[TBL] [Abstract][Full Text] [Related]
55. [Catecholamine, DOPA and vanilmandelic acid excretion in healthy subjects and depression patients of presenile age].
Kryzhanovskaia LA; Usherenko LS
Fiziol Zh; 1978; 24(4):511-8. PubMed ID: 680253
[No Abstract] [Full Text] [Related]
56. [Complex use of phenazepam, lithium and haloperidol in the treatment of several forms of schizophrenia].
Mosketi KV; Mokhovikov AN; Aksent'ev SB; Goĭkhberg IG; Kryzhanovskiĭ GN
Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(4):589-96. PubMed ID: 6730829
[TBL] [Abstract][Full Text] [Related]
57. [State of the sympthico-adrenal system in late pregnancy toxemias].
Strongina TN; Shekhtman MM; Bol'shakova TD; Lukicheva TI; Dibobes GK
Vopr Okhr Materin Det; 1972 May; 17(5):72-5. PubMed ID: 5029757
[No Abstract] [Full Text] [Related]
58. [Changes of catecholamine metabolism and symptoms of parkinsonism in rats with manganotoxicosis].
Samoĭlova ZT; Shavolina VA
Gig Tr Prof Zabol; 1974 Apr; 18(4):16-20. PubMed ID: 4845000
[No Abstract] [Full Text] [Related]
59. Sources and significance of plasma levels of catechols and their metabolites in humans.
Goldstein DS; Eisenhofer G; Kopin IJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):800-11. PubMed ID: 12649306
[TBL] [Abstract][Full Text] [Related]
60. Catecholamine metabolites in congenital sensory neuropathy with anhydrosis.
Shekim WO; Daniel AE; Koresko RL; Dekirmenjian H
Pediatrics; 1980 Jan; 65(1):154-7. PubMed ID: 7355015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
